Next |
home / stock / autl / autl message board
Subject | By | Source | When |
---|---|---|---|
Found an interesting article | jondoeuk | investorshub | 05/11/2023 6:32:42 PM |
$AUTL good read | jondoeuk | investorshub | 05/11/2023 10:18:44 AM |
great article | jondoeuk | investorshub | 05/11/2023 6:41:46 AM |
The now last up | jondoeuk | investorshub | 05/11/2023 4:44:23 AM |
MomentumIts now last up | jondoeuk | investorshub | 05/09/2023 11:12:12 AM |
$AUTL got some short data | jondoeuk | investorshub | 05/08/2023 9:42:32 PM |
and the shorts continue | jondoeuk | investorshub | 05/08/2023 6:48:25 AM |
Another oral presentation is planned for a different | jondoeuk | investorshub | 05/07/2023 10:14:39 PM |
The now last up | jondoeuk | investorshub | 05/06/2023 8:02:54 PM |
$AUTL Price now | jondoeuk | investorshub | 05/06/2023 7:19:57 AM |
bears and bulls | jondoeuk | investorshub | 05/05/2023 1:12:36 AM |
ASCO Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), | jondoeuk | investorshub | 04/30/2023 5:26:22 PM |
Another paper https://www.biorxiv.org/content/10.1101/2023.04.26.538403v1 | jondoeuk | investorshub | 04/29/2023 11:23:07 PM |
New preclinical data https://www.biorxiv.org/content/10.1101/2023.04.24.538039v1 | jondoeuk | investorshub | 04/28/2023 9:31:45 PM |
MomentumIts gaining | jondoeuk | investorshub | 04/27/2023 9:19:43 AM |
bears are running | jondoeuk | investorshub | 04/25/2023 7:51:21 AM |
When is this gonna take off? | stockguard | investorshub | 04/22/2023 8:55:29 PM |
$AUTL The now last trade up | jondoeuk | investorshub | 04/21/2023 5:15:06 PM |
$AUTL Price trading | jondoeuk | investorshub | 04/19/2023 10:32:43 AM |
and the shorts continue | jondoeuk | investorshub | 04/18/2023 12:24:10 AM |
News, Short Squeeze, Breakout and More Instantly...
Autolus Therapeutics plc Company Name:
AUTL Stock Symbol:
NASDAQ Market:
Autolus Therapeutics plc Website:
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated wi...
Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHA Two patients enrolled in Phase 1 Systemic Lupus Erythematosus (SLE) trial; study on track for initial data end of 2024 Market Authorization Application (M...